tradingkey.logo
tradingkey.logo
Pesquisar

Biomerica Inc

BMRA
Adicionar à lista de desejos
2.340USD
-0.090-3.70%
Fechamento 05/15, 16:00ETCotações atrasadas em 15 min
7.23MValor de mercado
PerdaP/L TTM

Mais detalhes de Biomerica Inc Empresa

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.

Informações de Biomerica Inc

Código da empresaBMRA
Nome da EmpresaBiomerica Inc
Data de listagemMar 17, 1980
CEOIrani (Zackary S)
Número de funcionários53
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 17
Endereço17571 Von Karman Avenue
CidadeIRVINE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92614
Telefone19493792875
Sitehttps://biomerica.com/
Código da empresaBMRA
Data de listagemMar 17, 1980
CEOIrani (Zackary S)

Executivos da empresa Biomerica Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
219.13K
+23.96%
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
64.53K
+61.98%
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
41.25K
+48.48%
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
32.50K
+69.23%
Mr. Allen C. Barbieri
Mr. Allen C. Barbieri
Executive Vice Chairperson of the Board and Corporate Secretary
Executive Vice Chairperson of the Board and Corporate Secretary
--
--
Dr. Jane F. Emerson, M.D., Ph.D.
Dr. Jane F. Emerson, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Madel
Mr. Scott Madel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Gary M. Huff
Mr. Gary M. Huff
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
219.13K
+23.96%
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
64.53K
+61.98%
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
41.25K
+48.48%
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
32.50K
+69.23%
Mr. Allen C. Barbieri
Mr. Allen C. Barbieri
Executive Vice Chairperson of the Board and Corporate Secretary
Executive Vice Chairperson of the Board and Corporate Secretary
--
--
Dr. Jane F. Emerson, M.D., Ph.D.
Dr. Jane F. Emerson, M.D., Ph.D.
Independent Director
Independent Director
--
--

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2026Q2
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
Clinical Lab
676.00K
55.87%
OTC
361.00K
29.83%
Contract Manufacturing
172.00K
14.21%
Physicians’ Office
1.00K
0.08%
Por RegiãoUSD
Nome
Receita
Proporção
United States
443.00K
36.61%
Asia
358.00K
29.59%
Europe
262.00K
21.65%
Middle East
137.00K
11.32%
South America
10.00K
0.83%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Clinical Lab
676.00K
55.87%
OTC
361.00K
29.83%
Contract Manufacturing
172.00K
14.21%
Physicians’ Office
1.00K
0.08%

Distribuição de ações

Atualizado em: qui, 14 de mai
Atualizado em: qui, 14 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Irani (Zackary S)
7.09%
Barbieri (Allen)
2.18%
Lu (Gary)
2.09%
Moatazedi (David)
1.33%
Chin (Eric)
1.05%
Outro
86.26%
Investidores
Investidores
Proporção
Irani (Zackary S)
7.09%
Barbieri (Allen)
2.18%
Lu (Gary)
2.09%
Moatazedi (David)
1.33%
Chin (Eric)
1.05%
Outro
86.26%
Tipos de investidores
Investidores
Proporção
Individual Investor
15.24%
Investment Advisor
2.32%
Investment Advisor/Hedge Fund
0.65%
Research Firm
0.08%
Outro
81.71%

Participação acionária institucional

Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
59
94.38K
3.05%
-250.59K
2025Q4
61
88.80K
11.10%
--
2025Q3
66
109.78K
12.53%
+19.30K
2025Q2
64
90.48K
15.22%
-57.30K
2025Q1
68
147.78K
21.33%
-341.18K
2024Q4
67
244.57K
22.09%
-15.39K
2024Q3
66
259.96K
25.76%
-100.07K
2024Q2
66
360.04K
29.98%
-224.63K
2024Q1
64
584.66K
28.76%
-20.09K
2023Q4
60
562.02K
30.44%
-39.83K
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Irani (Zackary S)
219.13K
7.26%
+52.50K
+31.51%
Dec 12, 2025
Barbieri (Allen)
67.29K
2.23%
+30.00K
+80.44%
Dec 12, 2025
Lu (Gary)
64.53K
2.14%
+40.00K
+163.05%
Dec 12, 2025
Moatazedi (David)
41.25K
1.37%
+20.00K
+94.12%
Dec 12, 2025
Chin (Eric)
32.50K
1.08%
+22.50K
+225.00%
Dec 12, 2025
Emerson (Jane)
30.13K
1%
+30.13K
--
Oct 17, 2025
BlackRock Institutional Trust Company, N.A.
18.64K
0.62%
--
--
Dec 31, 2025
Geode Capital Management, L.L.C.
18.63K
0.62%
-2.36K
-11.23%
Dec 31, 2025
DRW Securities, LLC
16.93K
0.56%
+6.53K
+62.87%
Dec 31, 2025
Coste (Catherine)
16.10K
0.53%
+10.63K
+194.10%
Dec 13, 2024
Ver Mais

ETFs Relacionados

Nome
Proporção
Sem dados

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Apr 16, 2025
Merger
8→1
Data
Data ex-dividendo
Tipo
Proporção
Apr 16, 2025
Merger
8→1
KeyAI